Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection

NCT01711242 is registered in ClinicalTrials.gov with xie congying as lead sponsor.

NCT NCT01711242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01711242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection
Lead sponsor
xie congying
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
January 31, 2021
Enrollment
208 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer